Skip to main content
Canadian Journal of Surgery logoLink to Canadian Journal of Surgery
. 2011 Jun;54(3):201–205. doi: 10.1503/cjs.038109

Mammoplasty for symmetry in breast reconstruction and histologic assessment

Apollinaire Gninlgninrin Horo 1,, Olivier Acker 1, Etienne Roussel 1, Henri Marret 1, Gilles Body 1
PMCID: PMC3104318  PMID: 21443831

Abstract

Background

In breast reconstruction, complementary surgery on the contralateral breast is sometimes necessary to obtain a satisfactory aesthetic result. This complementary mammoplasty for symmetry gives the surgeon the opportunity to verify the state of the mammary glandular tissue to rule out a possible occult tumour in the contralateral breast. Our objective was to determine the prevalence of borderline lesions and of in situ and invasive carcinoma in specimens of the contralateral breast in a mammoplasty for symmetry in patients with breast cancer.

Methods

We conducted a retrospective study of 145 breast reconstructions with mammoplasty for symmetry conducted at the Tours Regional Teaching Hospital in France.

Results

The glandular histologic result after mammoplasty was normal in 45.5% of patients, with benign pathologies in 38.9% and borderline lesions in 15.6% of patients. No invasive or in situ carcinoma was detected.

Conclusion

Systematic histologic analysis of glandular mammary tissue sampled after reduction mammoplasty in the particular context of breast reconstruction after breast cancer makes it possible to discover lesions that were not seen in presurgical evaluation. The early management of these borderline occult lesions could reduce the incidence of breast cancer in these at-risk patients.


An early diagnosis and the therapeutic approach to the management of breast cancer profoundly modify women’s behaviour and their quality of life.1 Moreover, mastectomy is often experienced as a self-image wound with an important impact on sex life. The fear of relapse is compounded in these patients by feelings of shame and guilt.

It has been suggested that patients who undergo a conservative treatment have a better quality of life than patients have mastectomies.2 However, not all authors have found this difference between both types of treatment in long-term follow-up (bias related to age at the time of cancer diagnosis or to the anxiety caused by the risk of relapse); however, they all agree that a conservative treatment has less impact on body image.2,3

For some 20 years, cancer surgery has improved with glandular modelling techniques borrowed from plastic surgery to reduce the consequence of radical breast surgery. It is now proven that breast reconstruction has a favourable incidence on quality of life, regardless of the technique used.2,4 The surgical treatment of breast cancer presently includes as a matter of course the partial or total repair of the amputated breast. These surgical techniques have improved constantly since their inception.5

In breast reconstruction, complementary surgery on the contralateral breast is sometimes necessary to obtain a satisfactory aesthetic result. This complementary surgery gives the surgeon the opportunity to analyze the state of a specimen of glandular tissue to rule out a possible occult tumour in the contralateral breast.

The objective of this study was to determine the prevalence of borderline lesions and of in situ and invasive carcinoma in specimens of the contralateral breast in mammoplasty for symmetry in patients with breast cancer. We analyzed 10 years of breast reconstruction practice in the gynecology department of the Tours Regional Teaching Hospital in France.

Methods

We conducted a retrospective cohort study for the period of Jan. 1, 1996, to July 31, 2006, in the gynecology department of the Olympe de Gouges Centre of the Bretonneau Hospital campus of the Tours Regional Teaching Hospital. The study examined the cases of all patients who underwent breast reconstruction for breast cancer, regardless of the technique used (simple prosthesis, latissimus dorsi musculocutaneous flap with or without prosthetics, transverse rectus abdominis musculocutaneous [TRAM] flap), associated with a mammoplasty for symmetry. This secondary surgery was systematically performed well after the conclusion of adjuvant treatments (chemotherapy and radiotherapy), on average after 44 (range 3–188) months. In this series there was breast reconstruction in the primary surgery.

Patients who underwent a mammoplasty without glandular resection (mastopexy, augmentation mammoplasty by simple prosthesis) and those who had a history of cancer of the contralateral breast were excluded from the study.

The presurgical screening of the contralateral breast was performed by mammography. The number of contralateral cancers that may have been identified by imaging before the surgery for symmetry, a result which would have excluded this surgery, could not be specified because of the retrospective nature of the study.

Histopathologic analysis protocol of glandular resections during reduction mammoplasty

The resected glandular tissue was assessed for weight in the operating room, and it was sent without orientation marks to the pathology laboratory. The resected glandular tissue was submitted to macroscopic examination then fixated in 10% formalin for 24–48 hours. In the absence of a macroscopically detectable lesion, 3 samples were systematically obtained; otherwise, the macroscopically detectable lesion was totally removed. The histology samples were embedded in paraffin. Thin sections (4 μm) from the inclusion blocks were sliced with a microtome. The sections were stained with hematin-eosin-saffron and mounted with Eukitt medium. Histologic sections were examined with an optic microscope.

Evaluation criteria

The histologic analysis of samplings helped us to classify them in 4 groups:

  • normal tissue (absence of abnormalities),

  • benign pathologies (benign mastopathies, simple ductal hyperplasia),

  • borderline lesions (atypical ductal hyperplasia [ADH], intralobular neoplasia), and

  • carcinomas.

Results

A total of 273 breast reconstructions were recorded during the study period; of these, 145 included mammoplasty for symmetry (mastopexy, reduction or augmentation mammoplasty) of the remaining breast (Fig. 1). A total of 68 records were excluded owing to the mammoplasty not including glandular resection and history of cancer.

Fig. 1.

Fig. 1

Patient inclusion criteria for a retrospective cohort study of 145 breast reconstructions with mammoplasty for symmetry conducted at the Tours Regional Teaching Hospital (France).

The epidemiologic characteristics of the 145 patients with breast reconstruction are summarized in Table 1. Histologic study of the cancer found predominantly invasive ductal carcinoma (60%). Among the patients, 71% had received an auxiliary treatment, mostly radiotherapy and chemotherapy.

Table 1.

Epidemiologic, histologic and therapeutic characteristics of patients who underwent mammoplasty for symmetry between Jan. 1, 1996, and July 31, 2006

Characteristic No. (%)*
Age, mean (range) yr 53.8 (33–75)
Histologic characteristics of cancer
 Invasive ductal carcinoma 88 (60.7)
 Invasive lobular carcinoma 13 (8.9)
 Ductal carcinoma in situ 43 (29.7)
 Mucinous carcinoma 1 (0.7)
Previous adjuvant treatment 103 (71.0)
 Radiotherapy 95 (92.2)
 Chemotherapy 77 (74.8)
 Hormone therapy 51 (49.5)
Techniques of breast reconstruction
 Simple prosthesis 47 (32.4)
 Latissimus dorsi musculocutaneous flap 79 (54.5)
 TRAM flap 19 (13.1)

TRAM = transverse rectus abdominis musculoscutaneous.

*

Unless otherwise indicated.

The results for the specimens concerned 77 women who underwent a mammoplasty of the contralateral breast with glandular resection. Among these women, 55.3% had a mammoplasty of the right breast compared with 44.7% who had a mammoplasty of the left breast. During these mammoplasties, on average, 143.4 (range 30–1720) g of glandular tissue was resected.

Table 2 presents the results of the histologic analysis: normal in 35 (45.5%) women, benign pathologies in 30 (38.9%) women and borderline lesions in 12 (15.6%) women. No invasive or in situ carcinoma was detected.

Table 2.

Histologic findings of glandular samplings after reduction mammoplasty

Histology No. (%)
Normal tissue
 Normal parenchyma 35 (45.4)
 Benign mastopathy 20 (26.0)
Benign pathology
 Simple ductal hyperplasia 10 (13.0)
 Intralobular neoplasia 8 (10.4)
Borderline lesions
 Atypical ductal hyperplasia 4 (5.2)
Carcinoma
 Ductal carcinoma in situ
 Invasive carcinoma
Total 77 (100)

Discussion

Few authors have assessed the incidence of occult lesions in the other breast in this particular context of mammoplasty with a treated cancer of the contralateral breast. Ricci and colleagues6 have carried out a study similar to ours by comparing prospectively the detection of synchronous and metachronous cancer in the contralateral breast. The authors reported rates of 1.8% for invasive carcinoma and 2.6% for in situ carcinoma among synchronous cancers and of 1.8% for metachronous cancers. The difference could be related to patients’ preoperative management, to a recruitment bias or to the impact of auxiliary treatment.

The importance of glandular resections and the number of blocks in histology can also influence the results considerably, particularly when there are no macroscopic abnormalities.

The limited glandular volume and size of the specimens in our series did not make it possible to reveal occult carcinomas. Nevertheless, the presence of borderline lesions (15.6%) demonstrates the importance of histologic verification in these at-risk women.

Two studies7,8 have mentioned the opportunity offered by mammoplasty for the diagnosis of occult borderline breast lesions in these women who present a risk of breast cancer.

Cook and Fuller7 conducted a global study of 1289 specimens from reduction mammoplasties conducted for both aesthetic and breast reconstruction reasons. They found borderline lesions in 26 (2%) patients, in situ or micro-invasive cancer in 4 (0.3%) patients and invasive cancer in 1 (0.08%) patient. This cancer was diagnosed in a woman who had undergone breast reconstruction after breast cancer.

The contralateral breast presents a high risk of asynchronous or even bilateral location of the primitive tumour. The probability of cancer in the contralateral breast after a primitive tumour of the breast is 2–6 times higher in comparison to the general population of women, hence the recommendation of pre- and postoperative assessment of this breast.9,10

In the context of aesthetic surgery with lower risks of breast cancer, occult lesions have nevertheless been discovered, as shown in several studies.8,11 Dotto and colleagues8 assessed 516 reduction mammoplasties over a 15-year period and found only borderline and benign lesions like the ones in found our series.

Other authors, including Viana and colleagues,11 have reported carcinomas (in situ carcinoma 0.3% and invasive carcinoma 0.3%). Kakagia and colleagues12 reported the results of a histologic analysis of 314 reduction plasties in women without any family history of breast cancer. The authors found invasive lobular carcinoma in 0.6% of patients, ductal carcinoma in situ in 0.3% of patients and ADH in 1.6% of patients. Colwell and colleagues13 analyzed a larger sample (800 women) and found invasive carcinomas in 0.4% and carcinoma in situ in 0.4% of patients. Colleau and colleagues14 reported invasive lobular carcinoma in 2 (0.2%) patients, carcinoma in situ in 4 (0.5%) patients and a lobular carcinoma in situ in 1 (0.1%) patient.

The probability of discovering occult lesions during breast plasties increases with age. Hage and Karim15 estimated that the risk of discovering a carcinoma increases from 0.05% to 0.11% in women over the age of 50 years.

An assessment of the impact of cancers discovered fortuitously was conducted by Ricci and colleagues,6 who showed that there was no impact on patient survival. However, because of the limited number of patients, this conclusion cannot be considered firm.

There have been many discussions of the results of histologic analyses, particularly of ductal and lobular epithelial proliferations. Discussions have concerned their classification and significance with regard to a later occurrence of an invasive lesion. Several concepts that had been previously considered established are presently questioned. Most authors consider that simple ductal hyperplasia does not present a substantial increase of the risk of onset of invasive carcinoma and therefore do not consider it as a precursor (relative risk 1.2–2). Conversely ADH presents a relative risk factor of 4–5. An invasive carcinoma will develop in a mean period of 8.3 years in 4%–22% of women who are carriers of ADH.16

Concerning lobular proliferations, their nomenclature and classification are disputed. It is recognized that lobular neoplasias are an indicator of the risk of invasive carcinoma. However, they are not considered true precursors. Some studies have questioned this view. They are difficult to evaluate because these are lesions that have no clinical, radiologic and even macroscopic translations. According to the studies, their incidence varies from 0.5% to 3.8% of biopsies.17

The management of all of these borderline lesions is not codified and varies according to the teams. In our series, the margins of resection of occult lesions discovered on the operative specimens were negative.

To reduce the incidence of these occult tumours, authors insist on the preoperative assessment of patients. Some argue that a systematic mammography is required,7 whereas others argue that systematic mammography be reserved to women aged 40 years and older.16 However, they all agree on the histologic assessment and on the orientation and marking of all tissue fragments obtained.

The improvement of screening techniques should eventually help reduce the number of occult invasive or in situ carcinomas discovered at mammoplasty.7,14 Some authors have suggested systematic reduction mammoplasty for prevention in women who have a family history of breast cancer.18

What could magnetic resonance imaging (MRI) contribute to presurgical detection of occult lesions in the contralateral breast? Brennan and colleagues19 tried to answer this question by conducting a meta-analysis of 3253 women. They found that MRI had a 47.9% (confidence interval [CI] 31.8–64.6) positive predictive value when considering all data, an additional detection rate of cancers of 4.1%, and a rate of false-positive and false-negative results of 9.3% (CI 5.8–14.7). Therefore, MRI can detect an important proportion of occult lesions, but the high rate of false-positive results makes it necessary to use additional means of investigation.

Conclusion

A systematic histologic analysis of glandular tissue obtained during reduction mammoplasty in the particular context of breast reconstruction after breast cancer helps discover lesions that were not detected in the presurgery assessment. The early management of these occult borderline lesions could help reduce the number of breast cancers in these at-risk patients.

Footnotes

Competing interests: None declared.

Contributors: Drs. Horo, Acker and Body designed the study. Dr. Horo acquired the data, which he and Drs. Acker and Roussel analyzed. Dr. Horo wrote the article, which all other authors reviewed. All authors approved the final version for publication.

References

  • 1.Burgess C, Cornelius V, Love S, et al. Depression and anxiety in women with early breast cancer: five year observational cohort study. BMJ. 2005;330:702. doi: 10.1136/bmj.38343.670868.D3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Curran D, van Dongen JP, Aaronson NK, et al. Quality of life of early-stage breast cancer patients treated with radical mastectomy or breast-conserving procedures: results of EORTC trial 10801. The European Organization for Research and Treatment Cancer (EORTC). Breast Cancer Co-operative Group (BCCG) Eur J Cancer. 1998;34:307–14. doi: 10.1016/s0959-8049(97)00312-2. [DOI] [PubMed] [Google Scholar]
  • 3.Montazeri A. Health-related quality of life in breast cancer patients: a bibliographic review of the literature from 1974 to 2007. J Exp Clin Cancer Res. 2008;27:32. doi: 10.1186/1756-9966-27-32. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Keith DJ, Walker MB, Walker LG, et al. Women who wish breast reconstruction: characteristics, fears, and hopes. Plast Reconstr Surg. 2003;111:1051–6. doi: 10.1097/01.PRS.0000046247.56810.40. [DOI] [PubMed] [Google Scholar]
  • 5.Clough KB. Chirurgie oncoplastique du sein [Article in French] Ref Gynecol Obstet. 2005;11:S101–7. [Google Scholar]
  • 6.Ricci MD, Munhoz AM, Pinotti M, et al. The influence of reduction mammaplasty techniques in synchronous breast cancer diagnosis and metachronous breast cancer prevention. Ann Plast Surg. 2006;57:125–32. doi: 10.1097/01.sap.0000216245.16475.b9. [DOI] [PubMed] [Google Scholar]
  • 7.Cook IS, Fuller CE. Does histopathological examination of breast reduction specimens affect patient management and clinical follow up. J Clin Pathol. 2004;57:286–9. doi: 10.1136/jcp.2003.012427. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Dotto J, Kluk M, Geramizadeh B, et al. Frequency of clinically occult intraepithelial and invasive neoplasia in reduction mammoplasty specimens: a study of 516 cases. Int J Surg Pathol. 2008;16:25–30. doi: 10.1177/1066896907307176. [DOI] [PubMed] [Google Scholar]
  • 9.Chen Y, Thompson W, Semenciw R, et al. Epidemiology of contralateral breast cancer. Cancer Epidemiol Biomarkers Prev. 1999;8:855–61. [PubMed] [Google Scholar]
  • 10.Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol, 1996;14:2738–46. doi: 10.1200/JCO.1996.14.10.2738. [DOI] [PubMed] [Google Scholar]
  • 11.Viana GA, Pitanguy I, Torres E. Histopathological findings in surgical specimens obtained from reduction mammaplasties. Breast. 2005;14:242–8. doi: 10.1016/j.breast.2004.12.006. [DOI] [PubMed] [Google Scholar]
  • 12.Kakagia D, Fragiab K, Grekouc A. Reduction mammaplasty specimens and occult breast carcinomas. Eur J Surg Oncol. 2005;31:19–21. doi: 10.1016/j.ejso.2004.07.026. [DOI] [PubMed] [Google Scholar]
  • 13.Colwell AS, Kukreja J, Breuing KH, et al. Occult breast carcinoma in reduction mammaplasty specimens: 14 years experience. Plast Reconstr Surg. 2004;113:1984–8. doi: 10.1097/01.prs.0000122212.37703.6e. [DOI] [PubMed] [Google Scholar]
  • 14.Colleau M, Magalon G, Bonnier P. Cancer du sein diagnostiqué par la réduction mammaire. Étude rétrospective sur une période de trois ans [Article in French] Ann Chir Plast Esthet. 2005;50:127–33. doi: 10.1016/j.anplas.2004.11.008. [DOI] [PubMed] [Google Scholar]
  • 15.Hage JJ, Karim RB. Risk of breast cancer among reduction mammoplasty patients and the strategies used by plastic surgeons to detect such cancer. Plast Reconstr Surg. 2006;117:727–35. doi: 10.1097/01.prs.0000200060.33601.2a. [DOI] [PubMed] [Google Scholar]
  • 16.Dauplat MM, Penault-Llorca F. Classification des lésions pré-invasives et des carcinomes in situ: doutes, controverses, propositions de nouvelles classifications [Article in French] Bull Cancer. 2004;91(Suppl):S205–10. [PubMed] [Google Scholar]
  • 17.Purushotham AD. The diagnosis and management of pre-invasive breast disease. Problems associated with management of pre-invasive lesion. Breast Cancer Res. 2003;5:309–12. doi: 10.1186/bcr649. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Palmieri B, Benuzzi G, Costa A, et al. Breast reduction and subsequent cancer: a prophylactic perspective. Breast. 2006;15:476–81. doi: 10.1016/j.breast.2005.09.011. [DOI] [PubMed] [Google Scholar]
  • 19.Brennan ME, Houssami N, Lord S, et al. Magnetic resonance imaging screening of the contralateral breast in women with newly diagnosed breast cancer: systematic review and meta-analysis of incremental cancer detection and impact on surgical management. J Clin Oncol. 2009;27:5640–9. doi: 10.1200/JCO.2008.21.5756. [DOI] [PubMed] [Google Scholar]

Articles from Canadian Journal of Surgery are provided here courtesy of Canadian Medical Association

RESOURCES